Becton, Dickinson and Company (NYSE:BDX) Issues FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.95-13.15 for the period, compared to the consensus estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Becton, Dickinson and Company Trading Down 2.4 %

Becton, Dickinson and Company stock traded down $5.67 during trading on Friday, hitting $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The stock’s fifty day moving average is $238.45 and its 200 day moving average is $240.53. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The stock has a market capitalization of $67.80 billion, a price-to-earnings ratio of 51.69, a P/E/G ratio of 1.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the company earned $2.86 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Wall Street Analysts Forecast Growth

Separately, Barclays raised their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an overweight rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $280.00.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.